Experimental prescription, rising resistance: the alarming misuse of ceftazidime-avibactam in healthcare systems.
作者信息
Akbari Mojtaba, Giske Christian G, Solgi Hamid
机构信息
Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
出版信息
Iran J Microbiol. 2024 Dec;16(6):720-721. doi: 10.18502/ijm.v16i6.17243.
Abstract
摘要
相似文献
1
Experimental prescription, rising resistance: the alarming misuse of ceftazidime-avibactam in healthcare systems.实验性处方，耐药性上升：医疗系统中头孢他啶-阿维巴坦的惊人滥用情况
Iran J Microbiol. 2024 Dec;16(6):720-721. doi: 10.18502/ijm.v16i6.17243.
2
The importance of monitoring a new antibiotic: ceftazidime/avibactam usage and resistance experience from England, 2016 to 2020.监测一种新型抗生素的重要性：2016年至2020年英格兰头孢他啶/阿维巴坦的使用情况及耐药性经验
Euro Surveill. 2025 Apr;30(14). doi: 10.2807/1560-7917.ES.2025.30.14.2400399.
3
Role of Ceftazidime-Avibactam in Urinary Tract Infections Caused by Carbapenem-Resistant Enterobacterales.头孢他啶-阿维巴坦在耐碳青霉烯类肠杆菌科细菌引起的尿路感染中的作用
Cureus. 2024 Dec 6;16(12):e75221. doi: 10.7759/cureus.75221. eCollection 2024 Dec.
4
Real-world utilization of ceftazidime/avibactam among inpatients in the national Veterans Affairs Healthcare System.在国家退伍军人事务医疗保健系统中，住院患者中头孢他啶/阿维巴坦的实际应用。
Am J Health Syst Pharm. 2024 Jun 11;81(12):509-520. doi: 10.1093/ajhp/zxae038.
5
In vitro activity of ceftazidime-avibactam/aztreonam combination against MBL-producing Pseudomonas aeruginosa strains.头孢他啶-阿维巴坦/氨曲南联合用药对产金属β-内酰胺酶铜绿假单胞菌菌株的体外活性
Infection. 2024 Nov 18. doi: 10.1007/s15010-024-02425-4.
6
Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview.耐头孢他啶-阿维巴坦的肺炎克雷伯菌碳青霉烯酶变异体：进化概述。
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0044722. doi: 10.1128/aac.00447-22. Epub 2022 Aug 18.
7
In vivo emergence of cefiderocol and ceftazidime/avibactam cross-resistance in KPC-producing Klebsiella pneumoniae following ceftazidime/avibactam -based therapies.产碳青霉烯酶肺炎克雷伯菌在接受头孢他啶/阿维巴坦治疗后体内出现头孢地尔和头孢他啶/阿维巴坦交叉耐药性。
Diagn Microbiol Infect Dis. 2024 Sep;110(1):116372. doi: 10.1016/j.diagmicrobio.2024.116372. Epub 2024 May 21.
8
The Effect of β-Lactam Antibiotics on the Evolution of Ceftazidime/Avibactam and Cefiderocol Resistance in KPC-Producing Klebsiella pneumoniae.β-内酰胺类抗生素对产 KPC 肺炎克雷伯菌中头孢他啶/阿维巴坦和头孢地尔耐药演变的影响。
Antimicrob Agents Chemother. 2023 Mar 16;67(3):e0127922. doi: 10.1128/aac.01279-22. Epub 2023 Feb 16.
9
Investigation of ceftazidime-avibactam susceptibility in clinical isolates of gram-negative bacteria.革兰氏阴性菌临床分离株中头孢他啶-阿维巴坦药敏性的研究。
Turk J Med Sci. 2022 Dec;52(6):1839-1844. doi: 10.55730/1300-0144.5530. Epub 2022 Dec 21.
10
German Multicenter Study Analyzing Antimicrobial Activity of Ceftazidime-Avibactam of Clinical Meropenem-Resistant Isolates Using a Commercially Available Broth Microdilution Assay.德国多中心研究：使用市售肉汤微量稀释法分析头孢他啶-阿维巴坦对临床耐美罗培南菌株的抗菌活性
Antibiotics (Basel). 2022 Apr 19;11(5):545. doi: 10.3390/antibiotics11050545.
本文引用的文献
1
Failure of ceftazidime/avibactam experimental therapy in the treatment of Klebsiella pneumoniae ST11 co-producing NDM-1 and OXA-48 carbapenemases infection.头孢他啶/阿维巴坦实验治疗治疗产 NDM-1 和 OXA-48 碳青霉烯酶肺炎克雷伯菌 ST11 感染失败。
Eur J Clin Microbiol Infect Dis. 2024 Oct;43(10):2023-2027. doi: 10.1007/s10096-024-04911-x. Epub 2024 Jul 29.
2
Role of β-Lactamase Inhibitors as Potentiators in Antimicrobial Chemotherapy Targeting Gram-Negative Bacteria.β-内酰胺酶抑制剂作为增效剂在针对革兰氏阴性菌的抗菌化疗中的作用。
Antibiotics (Basel). 2024 Mar 15;13(3):260. doi: 10.3390/antibiotics13030260.
3
High prevalence of OXA-48-like and NDM carbapenemases among carbapenem resistant of clinical origin from Iran.来自伊朗临床分离的耐碳青霉烯类细菌中，OXA-48样和NDM碳青霉烯酶的高流行率。
Iran J Microbiol. 2023 Oct;15(5):609-615. doi: 10.18502/ijm.v15i5.13866.
4
Loss of exclusivity of ceftazidime/avibactam in low- and middle-income countries: a test for antibiotic stewardship practice.头孢他啶/阿维巴坦在低收入和中等收入国家失去独家地位：对抗生素管理实践的一次考验。
Lancet Reg Health Southeast Asia. 2023 May 27;15:100225. doi: 10.1016/j.lansea.2023.100225. eCollection 2023 Aug.
5
Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections.碳青霉烯类耐药革兰氏阴性菌感染的治疗选择。
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S565-S575. doi: 10.1093/cid/ciz830.
Zotero 插件